(Press-News.org) PHILADELPHIA--Treating metastatic melanoma with a triple threat--including radiation therapy and two immunotherapies that target the CTLA4 and PD-1 pathways--could elicit an optimal response in more patients, one that will boost the immune system's attack on the disease, suggests a new study from a multidisciplinary team of researchers from Penn's Abramson Cancer Center published today in Nature.
The study, led by senior authors Andy J. Minn, MD, PhD, assistant professor of Radiation Oncology, Robert Vonderheide, MD, DPhil, the Hanna Wise Professor in Cancer Research, Amit Maity, MD, PhD, professor of Radiation Oncology, and E. John Wherry, PhD, professor of Microbiology and director of the Institute for Immunology at the Perelman School of Medicine at the University of Pennsylvania, reports for the first time on the response and resistance to radiation combined with ipilimumab (an antibody against CTLA4) in both patients and mice.
In the phase I clinical study, known as the "RadVax" trial, the team found that combining ipilimumab with radiation was safe and shrank tumors in a subset of 22 metastatic melanoma patients (18 percent). The concurrent mouse study shed light on a mechanism of resistance, known as the PD-L1 pathway, found in many patients whose cancers progressed, suggesting that an antibody against PD-L1 or its partner PD-1 is an ideal third treatment to improve response and immunity.
"These new immunotherapies are potent treatment options that have generated a lot of excitement in the past few years, but we know that many patients fail to respond, underscoring the need to further improve the drugs' abilities," Minn said. "Anecdotally, we know that combining radiation with immunotherapy can be powerful, so we were very motivated to move forward with both a clinical trial to demonstrate that this combination is a promising route to pursue and with laboratory studies to understand why response happens and why it does not."
Ipilimumab is an FDA-approved, anti-CTLA4 antibody that serves to lift a break on the immune system, allowing T cells to infiltrate and attack tumor cells. Antibodies that block the PD-L1 pathway, which cancer cells use to hide from the immune system, include pembrolizumab or nivolumab, anti-PD-1 immunotherapies approved by the FDA recently.
It is believed that adding radiation results in a synergistic attack, turning the destroyed tumor cells as a vaccine against the cancer. Irradiated tumor cells are believed to release antigens that help train the immune system to fight other tumors in the body. The treatment has earned the name "RadVax" because of its vaccine-like qualities.
The impetus for the Penn phase I clinical study was a metastatic melanoma patient in his early 50s who was treated with an anti-CTLA4 antibody at Penn Medicine by co-author Lynn M. Schuchter, MD, chief of Hematology/Oncology at Penn's Abramson Cancer Center. While on an anti-CTLA4 antibody, the patient's condition worsened, and he required palliative radiation therapy. Over the course of many months after both modalities and no further treatment, however, his metastatic cancer started to resolve, and he was eventually deemed nearly cancer free.
Attempting to mirror his treatment experience, the researchers recruited 22 previously treated and untreated stage IV melanoma patients for a phase I clinical trial that investigated the use of both modalities. The group received stereotactic body radiation therapy (SBRT) to a single tumor followed three to five days later with ipilimumab every three weeks for four cycles.
The team found that 18 percent of patients had partial response in unirradiated tumors, 18 percent had stable disease and 64 percent had progressive disease. The median progression free survival and overall survival for patients was 3.8 months and 10.7 months with a median follow up of 18.4 and 21.3 months, respectively. The group's overall survival rate was 35 percent. A past, phase III study showed an overall survival rate of 20 percent in patients on ipilimumab alone.
"This approach is changing the way we view radiation--from strictly a local form of therapy to one that may augment a systemic response when given with immunotherapy," Maity said.
The response in mice was met with similar results: 17 percent of mice responded to the combination of radiation therapy and an anti-CTLA4 antibody.
To better understand the mechanism of resistance observed in many of the patients, the researchers turned to the mice. Mouse tumors that relapsed after radiation and anti-CTLA4 revealed that PD-L1, known to inhibit the activation of T cells, was among the top upregulated genes that made up a "resistance gene signature," the authors reported. Indeed, mice with tumors showing high PD-L1 had disabled T cells and all failed treatment.
In mice, inhibiting PD-L1 restored both T cell function and tumor response to radiation therapy and anti-CTLA4, increasing survival to 60 percent. Going full circle back to the clinical trial, those patients with tumors showing high PD-L1 also had disabled T cells and all failed treatment, but patients with low PD-L1 tumors had 50 percent survival. The authors conclude that PD-L1 on tumor cells can be a dominant resistance mechanism to radiation therapy and ipilimumab.
"Understanding resistance is very important. Although outcome can be improved when more therapies are combined, risk of side effects can increase. Precision medicine requires knowing when to give more and what to give," said Minn. His lab focuses on cancer therapy resistance and recently published another report in Cell on the subject
"These results are extremely encouraging and will allow us to propel the work further, into bigger clinical studies investigating the triple threat," said Vonderheide, who is working with the team to start the clinical trials in other tumors, including pancreatic, lung and breast. "Once again, we are extending the reach of the immune system, and breaking the ceiling on what these drugs can do for our patients."
INFORMATION:
Co-authors include Christina Twyman-Saint Victor, Andrew J. Rech, Amit Maity, Ramesh Rengan, Kristen E. Pauken, Erietta Stelekati, Joseph L. Benci, Bihui Xu, Hannah Dada, Pamela M. Odorizzi, Ramin S. Herati, Kathleen D. Mansfield, Dana Patsch , Ravi K. Amaravadi,, Hemant Ishwaran, Rosemarie Mick, Daniel A. Pryma, Xiaowei Xu, Michael D. Feldman, Tara C. Gangadhar, and Stephen M. Hahn.
A collaborative effort between investigators at the Yerkes National Primate Research Center, Emory University School of Medicine and Georgia Institute of Technology has led to the development of a non-invasive method to image simian immunodeficiency virus (SIV) replication in real-time, in vivo.
This approach, which is reported today in Nature Methods' Advance Online Publication, is based on immune positron-emission tomography/computed tomography (PET/CT) and allows for the capture of viral dynamics of SIV, the animal model of human HIV infection. This novel approach ...
A new study of acute lymphoblastic leukemia (ALL), a blood cancer that primarily affects young children, has revealed that the disease has two distinct subtypes, and provides preliminary evidence that about 13 percent of ALL cases may be successfully treated with targeted drugs that have proved highly effective in the treatment of lymphomas in adults.
Usually emerging in children between 2 and 5 years of age, ALL occurs when the proliferation of white blood cells known as lymphocytes spirals out of control. The current standard of care for ALL employs high doses of chemotherapy ...
A process that is too fast to be measured and analysed. Yet a group of international scientists did not lose heart and conceived a sort of highly sophisticated moviola film-editing system, which allowed them to observe - for the first time in a direct manner - an effect underlying high-temperature conductivity. The results of their work have been published in Nature Physics on Monday 9 March 2015.
Superconductors have properties that make them potentially very interesting for technology (examples of application include magnetic levitation trains). The road to a true application ...
Narcoleptics suffer from bouts of sleepiness and sleep attacks, which impair their ability to function in daily life. But the precise cause of narcolepsy has long eluded scientists, and the cure for the devastating neurological disorder afflicting an estimated three million people worldwide -- and one in 3,000 Americans -- remains at bay.
A new study published in Pharmacological Research by the world's leading autoimmune disease expert, Tel Aviv University's Prof. Yehuda Shoenfeld, finds that narcolepsy bears the trademarks of a classic autoimmune disorder and should ...
BOSTON, MA - Healthcare spending is at an all-time high in the U.S., yet young African-American men see little benefit, according to Boston Medical Center (BMC) researchers' Viewpoint commentary published in the current issue of the Journal of the American Medical Association (JAMA).
The researchers note that black men have a life expectancy nearly five years less than white men. While heart disease and cancer contribute to this decreased life expectancy, homicide also plays a large role. From ages 1 to 14, homicide is either the second or third leading cause of death ...
The extraordinary promise of quantum information processing -- solving problems that classical computers can't, perfectly secure communication -- depends on a phenomenon called "entanglement," in which the physical states of different quantum particles become interrelated. But entanglement is very fragile, and the difficulty of preserving it is a major obstacle to developing practical quantum information systems.
In a series of papers since 2008, members of the Optical and Quantum Communications Group at MIT's Research Laboratory of Electronics have argued that optical ...
LINCOLN, NE - Turfgrass professionals have created seed mixes specifically blended to ensure disease and insect resistance, water use efficiency, and tolerance to traffic. For example, a commonly used mixture of kentucky bluegrass (KBG) and perennial ryegrass (PRG) seed offers advantages such as rapid germination and establishment and provides turf cover that can compete with weeds. A new study shows how initial composition of KBG:PRG in the seed mixture affects species composition over multiple years in the Midwest, and offers recommendations about seeding ratios for optimal ...
ROCHESTER, Minn. -- Inhaled Nitric Oxide (iNO) is a drug approved by the Food and Drug Administration that is commonly used in term and near-term neonates who have severe respiratory failure caused by pulmonary hypertension. Over the last decade there have been multiple large studies trying to determine a clinical use for iNO in preterm neonates, but despite evidence of short-term benefit, this drug has not been shown to improve long-term outcomes in preemies. Still, the drug is commonly being used in this population, Mayo Clinic Children's Center and co-authors say in ...
LAWRENCE -- Libya hasn't been terribly hospitable for scientific research lately.
Since the 2011 toppling of Muammar Gaddafi, fighters tied to various tribes, regions and religious factions have sewn chaos across that nation. Most recently, ISIS militants in Libya committed mass beheadings that triggered retaliatory bombings by neighboring Egypt.
"Currently, it is obviously very dangerous to be a Western scientist in Libya," said Christopher Beard, Distinguished Foundation Professor of Ecology and Evolutionary Biology at the University of Kansas. "Even Libyan citizens ...
Lots of potentially useful medical information is getting lost. McGill researchers discovered this when they looked into the lack of reporting of information from "stalled drug" trials in cancer, cardiovascular and neurological diseases.
"Stalled drugs" are drugs that fail to make it to the market either because they prove to be ineffective or unsafe or both. Because only one in ten of the drugs that goes into human testing actually gets licensed, most of the information collected in developing new drugs is currently being lost. This is despite the fact that this information ...
